25 Amendments of Marian-Jean MARINESCU related to 2020/2071(INI)
Amendment 7 #
Draft opinion
Recital A a (new)
Recital A a (new)
A a. Where as access to medicines is a growing problem within the Union, usually associated with the high price of medicines and hindering European citizens' right to access to health care, and whereas it is expected for the socio-economic situation to decline as a consequence of coronavirus pandemic and to worsen the living conditions for vulnerable citizens;
Amendment 9 #
Draft opinion
Recital A a (new)
Recital A a (new)
A a. Whereas access to medicines is a growing problem within EU, usually associated with the high price of medicines and hindering European citizens` right to access to health care; whereas it is expected for the socio- economic situation to decline as a consequence of coronavirus pandemic and to worsen the living conditions for vulnerable citizens;
Amendment 42 #
Motion for a resolution
Recital A a (new)
Recital A a (new)
Aa. whereas access to medicines is a growing problem within EU, usually associated with the high price of medicines and hindering European citizens` right to access to healthcare; whereas it is expected for the socio- economic situation to decline as a consequence of coronavirus pandemic and to worsen the living conditions for vulnerable citizens;
Amendment 75 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2 a. Insists that the Commission establishes shortage of medicines as one of the pillars of its new planned pharmaceutical strategy;
Amendment 79 #
Draft opinion
Paragraph 2 b (new)
Paragraph 2 b (new)
2 b. Calls on the Commission to reinforce the harmonized definition of medicine shortage, proposed by the EMA and HMA joint task force in 2019;
Amendment 81 #
Draft opinion
Paragraph 2 c (new)
Paragraph 2 c (new)
2 c. Encourages the Commission to create a fair pricing model for essential medicines, taking into account that prices should be more in line with the costs of research and development and considering the added therapeutic value;
Amendment 82 #
Draft opinion
Paragraph 2 d (new)
Paragraph 2 d (new)
2 d. Calls on the Commission to address supply quotas imposed by pharmaceutical manufacturers, which are a contributing factor to medicines shortages;
Amendment 83 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7 a. Insists that the Commission establishes shortage of medicines as one of the pillars of its new planned pharmaceutical strategy;
Amendment 86 #
Draft opinion
Paragraph 7 b (new)
Paragraph 7 b (new)
7 b. Encourages the Commission to create a fair pricing model for essential medicines, taking into account that prices should be more in line with the costs of research and development and considering the added therapeutic value;
Amendment 88 #
Draft opinion
Paragraph 7 c (new)
Paragraph 7 c (new)
7 c. Believes it is important that the Commission addresses the issue of legal parallel trade in order to prevent shortages due to exports caused by high differences in terms of prices of a medicine, between Member States;
Amendment 114 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Stresses the importance that the Commission addresses the issue of legal parallel trade in order to prevent shortages due to exports caused by high differences in terms of prices of a medicine, between Member States;
Amendment 134 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5 a. Calls on the Commission to take the first steps to enhance transparency of research and development costs of medicines;
Amendment 139 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5 b. Calls on the Commission to create a real time alert system on shortage of medicines in each Member State, based on EMA single point of contact network, in order to collect data from all EU for essential life-saving medicines shortages and to temporary restrict parallel trade until the respective shortage is restored;
Amendment 149 #
Draft opinion
Paragraph 5 c (new)
Paragraph 5 c (new)
Amendment 231 #
Motion for a resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Insists that the Commission establishes shortage of medicines as one of the pillars of its new planned pharmaceutical strategy;
Amendment 233 #
Motion for a resolution
Paragraph 2 b (new)
Paragraph 2 b (new)
2b. Encourages the Commission to create a fair pricing model for essential medicines, taking into account that prices should be more in line with the costs of research and development and considering the added therapeutic value;
Amendment 234 #
Motion for a resolution
Paragraph 2 c (new)
Paragraph 2 c (new)
2c. Calls on the Commission to address supply quotas imposed by pharmaceutical manufacturers, which are a contributing factor to medicines shortages;
Amendment 300 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Stresses the importance that the Commission addresses the issue of legal parallel trade in order to prevent shortages due to exports caused by high differences between Member States in terms of prices of a medicine;
Amendment 326 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls on the Commission to create a real time alert system on shortage of medicines in each Member State, based on EMA single point of contact network, in order to collect data from all EU for essential life-saving medicines shortages and to temporary restrict parallel trade until the respective shortage is restored;
Amendment 329 #
Motion for a resolution
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Calls on the Commission to include in the EU Statistics on Income and Living Conditions(EU-SILC) data on self-reported unmet needs regarding access to medicines, as so far access to medicines in not measured in the EU- SILC;
Amendment 345 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Urges the Commission and the Member States to introduce tax and financial incentives in return for appropriate commitments and to authorise state aid to encourage producers to locate their operations in Europe, from compound manufacturing to packaging and distribution; emphasises the strategic significance of this sector and the importance of investing in European companies, in the interests of resource diversification; all public funding being conditioned to the full transparency and traceability of investments, as well as to supply obligations on the European market and to accessible prices of medicine;
Amendment 461 #
Motion for a resolution
Paragraph 11 a (new)
Paragraph 11 a (new)
11a. Calls on the Commission to take the first steps to enhance transparency of research and development costs of medicines;
Amendment 538 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13a. Calls on the Commission to elaborate an European harmonised framework for a transparent pharmaceutical pricing policy taking in account the public money contribution for both research and subsidizing activities; moreover calls on the Commission to propose an European harmonized framework for a mechanism for national pricing and reimbursement systems in order to achieve a fair and sustainable pricing and procurement;
Amendment 556 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14a. Calls on the Commission to reinforce the harmonised definition of medicine shortage, proposed by the EMA and HMA joint task force in 2019;
Amendment 649 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Calls on the Commission to set up an innovative centralised digital platform for sharing information provided by national agencies and all stakeholder, based on the existing database of the National Medicines Verification Organization for sharing information provided by national agencies and all stakeholders including manufacturers, wholesalers and pharmacists, regarding available stocks regarding shortages of medicines and medical equipment; welcomes the introduction by the EMA of the SPOC and i-SPOC systems; calls for existing information systems to be improved so as to provide a clear overview of problems, shortages and requirements in each Member State, with a view to preventing stockpiling;